Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Pituitary Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1363050

The Clinical and Genetic Aspects of Six individuals with GH1 Variants and Isolated Growth Hormone Deficiency Type II

Provisionally accepted
  • Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, Fujian Province, China

The final, formatted version of the article will be published soon.

    Background: Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.Objective: This study aimed to identify causative variants in six Chinese families with IGHD II, exploring both clinical and genetic characteristics.Methods: Detailed clinical data, including clinical presentations, physical charateristics, medical and family histories, as well as genetic test results, were systematically examined.Results: Six children, comprising four males and two females, with a mean age of 4.64±1.15 years, exhibited short stature with a mean height of -3.95±1.41 SDS.Four of them had a family history of short stature, while one patient presented with pulmonary hypertension. All children demonstrated GH deficiency in growth hormone stimulation tests (mean peak GH value: 2.83 ± 2.46 ng/mL). Exome sequencing for the six patients and targeted gene sequencing for their family members revealed heterozygous variants in the GH1 gene, including Exon2-5del, c.334T>C, c.291+1G>A, c.291+2T>A, 1.5 kb deletion, and 1.7 kb deletion, with four variants being novel. Four patients underwent human recombinant growth hormone (rhGH) replacement therapy, initiating treatment at a mean age of 4.6±0.7 years. The mean height increase in patients was 1.21 ± 0.3 SDS in the first six months of treatment and 1.79 ± 0.15 SDS in the first year.Our findings contribute to expanding the genotypic and phenotypic spectra of individuals with IGHD II.

    Keywords: Gh1 gene, Growth hormone deficiency type II, short stature, pulmonary hypertension, rhGH treatment

    Received: 29 Dec 2023; Accepted: 16 Sep 2024.

    Copyright: © 2024 Chen, Huang, Chen, Shangguan, Wu, Ai and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ruimin Chen, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, Fujian Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.